CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive Gain (Loss)
Beginning Balance at Dec. 31, 2023	$ 394,971	$ 6	$ 926,269	$ (530,752)	$ (552)
Shares, Outstanding, Beginning Balance at Dec. 31, 2023		55,585,305
Issuance of common stock through at-the market sales agreement, net of issuance costs of $1.2 million, Shares		1,519,453
Issuance of common stock through at-the market sales agreement, net of issuance costs of $1.2 million	48,740		48,740
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs of $14.9 million	301,373		301,373
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs of $14.9 million, Shares		3,884,158
Exercise of stock options	3,933		3,933
Exercise of stock options, Shares		281,021
Vesting restricted stock, Shares		83,209
Stock-based compensation expense	11,968		11,968
Unrealized loss on marketable securities	(1,225)				(1,225)
Net loss	(48,557)			(48,557)
Ending Balance at Mar. 31, 2024	711,203	$ 6	1,292,283	(579,309)	(1,777)
Shares, Outstanding, Ending Balance at Mar. 31, 2024		61,353,146
Beginning Balance at Dec. 31, 2024	835,619	$ 7	1,591,707	(754,610)	(1,485)
Shares, Outstanding, Beginning Balance at Dec. 31, 2024		64,890,193
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs of $14.9 million	0
Exercise of stock options	535		535
Exercise of stock options, Shares		75,652
Vesting restricted stock, Shares		146,869
Stock-based compensation expense	14,233		14,233
Unrealized loss on marketable securities	1,427				1,427
Net loss	(65,581)			(65,581)
Ending Balance at Mar. 31, 2025	$ 786,233	$ 7	$ 1,606,475	$ (820,191)	$ (58)
Shares, Outstanding, Ending Balance at Mar. 31, 2025		65,112,714